RSK in tumorigenesis: Connections to steroid signaling

Steroids

Volumn 75, Issue 3, 2010, Pages 191-202

  Eisinger Mathason, T S Karin ^a,b   Andrade, Josefa ^a,b   Lannigan, Deborah A ^a,b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Androgen receptor; Estrogen receptor; MAPK pathway; p90 ribosomal S6 kinase; Tumorigenesis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN D1; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FLUOROMETHYL KETONE; MITOGEN ACTIVATED PROTEIN KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN SERINE THREONINE KINASE; PROTEIN SERINE THREONINE KINASE 2; PROTEIN SERINE THREONINE KINASE 3; PROTEIN SERINE THREONINE KINASE INHIBITOR; SL 0101; STEROID HORMONE; STEROID RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG; Y BOX BINDING PROTEIN 1;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; GENE CONTROL; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE OVEREXPRESSION; HORMONAL REGULATION; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MITOCHONDRIAL MEMBRANE; MULTIPLE MYELOMA; NONHUMAN; OSTEOSARCOMA; OVARY CANCER; PROSTATE CANCER; PROTEIN CONTENT; PROTEIN FUNCTION; PROTEIN INDUCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR PROMOTION;

CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; ENZYME ACTIVATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ISOENZYMES; NEOPLASMS; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; STEROIDS;

ANIMALIA;

EID: 76349124051     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2009.12.010     Document Type: Review

References (181)

1. Shupnik M.A. Crosstalk between steroid receptors and the c-Src-receptor tyrosine kinase pathways: implications for cell proliferation. Oncogene 23 (2004) 7979-7989
2. Cheskis B.J., Greger J., Cooch N., McNally C., McLarney S., Lam H.S., et al. MNAR plays an important role in ERa activation of Src/MAPK and PI3K/Akt signaling pathways. Steroids 73 (2008) 901-905
3. Fox E.M., Andrade J., and Shupnik M.A. Novel actions of estrogen to promote proliferation: integration of cytoplasmic and nuclear pathways. Steroids 74 (2009) 622-627
4. Sebolt-Leopold J.S., and Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4 (2004) 937-947
5. Dougherty M.K., Muller J., Ritt D.A., Zhou M., Zhou X.Z., Copeland T.D., et al. Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell 17 (2005) 215-224
6. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 118 (2008) 3003-3006
7. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118 (2008) 3065-3074
8. Friday B.B., and Adjei A.A. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin Cancer Res 14 (2008) 342-346
9. Adjei N.R.a.A. Inhibitors of Raf kinase and MEK signaling. Update Cancer Ther 2 (2007) 111-118
10. Carriere A., Ray H., Blenis J., and Roux P.P. The RSK factors of activating the Ras/MAPK signaling cascade. Front Biosci 13 (2008) 4258-4275
11. Roux P.P., and Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 68 (2004) 320-344
12. Clark D.E., Errington T.M., Smith J.A., Frierson Jr. H.F., Weber M.J., and Lannigan D.A. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res 65 (2005) 3108-3116
13. Law J.H., Habibi G., Hu K., Masoudi H., Wang M.Y., Stratford A.L., et al. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res 68 (2008) 10238-10246
14. Smith J.A., Poteet-Smith C.E., Xu Y., Errington T.M., Hecht S.M., and Lannigan D.A. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res 65 (2005) 1027-1034
15. Xian W., Pappas L., Pandya D., Selfors L.M., Derksen P.W., de Bruin M., et al. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Cancer Res (2009)
16. Tan Y., Ruan H., Demeter M.R., and Comb M.J. p90(RSK) blocks bad-mediated cell death via a protein kinase C-dependent pathway. J Biol Chem 274 (1999) 34859-34867
17. Dummler B.A., Hauge C., Silber J., Yntema H.G., Kruse L.S., Kofoed B., et al. Functional characterization of human RSK4, a new 90-kDa ribosomal S6 kinase, reveals constitutive activation in most cell types. J Biol Chem 280 (2005) 13304-13314
18. Bignone P.A., Lee K.Y., Liu Y., Emilion G., Finch J., Soosay A.E., et al. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer. Oncogene 26 (2007) 683-700
19. Thakur A., Rahman K.W., Wu J., Bollig A., Biliran H., Lin X., et al. Aberrant expression of X-linked genes RbAp46, Rsk4, and Cldn2 in breast cancer. Mol Cancer Res 5 (2007) 171-181
20. Myers A.P., Corson L.B., Rossant J., and Baker J.C. Characterization of mouse Rsk4 as an inhibitor of fibroblast growth factor-RAS-extracellular signal-regulated kinase signaling. Mol Cell Biol 24 (2004) 4255-4266
21. Cho Y.Y., Yao K., Kim H.G., Kang B.S., Zheng D., Bode A.M., et al. Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res 67 (2007) 8104-8112
22. Hurbin A., Coll J.L., Dubrez-Daloz L., Mari B., Auberger P., Brambilla C., et al. Cooperation of amphiregulin and insulin-like growth factor-1 inhibits Bax- and Bad-mediated apoptosis via a protein kinase C-dependent pathway in non-small cell lung cancer cells. J Biol Chem 280 (2005) 19757-19767
23. Dehan E., Bassermann F., Guardavaccaro D., Vasiliver-Shamis G., Cohen M., Lowes K.N., et al. betaTrCP- and Rsk1/2-mediated degradation of BimEL inhibits apoptosis. Mol Cell 33 (2009) 109-116
24. Eisenmann K.M., VanBrocklin M.W., Staffend N.A., Kitchen S.M., and Koo H.M. Mitogen-activated protein kinase pathway-dependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 63 (2003) 8330-8337
25. Pende M., Um S.H., Mieulet V., Sticker M., Goss V.L., Mestan J., et al. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway. Mol Cell Biol 24 (2004) 3112-3124
26. Jirstrom K., Ryden L., Anagnostaki L., Nordenskjold B., Stal O., Thorstenson S., et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol 58 (2005) 1135-1142
27. Thakur A., Sun Y., Bollig A., Wu J., Biliran H., Banerjee S., et al. Anti-invasive and antimetastatic activities of ribosomal protein S6 kinase 4 in breast cancer cells. Clin Cancer Res 14 (2008) 4427-4436
28. Thakur A., Xu H., Wang Y., Bollig A., Biliran H., and Liao J.D. The role of X-linked genes in breast cancer. Breast Cancer Res Treat 93 (2005) 135-143
29. Butt A.J., McNeil C.M., Musgrove E.A., and Sutherland R.L. Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E. Endocr Relat Cancer 12 Suppl. 1 (2005) S47-S59
30. Hanson K.D., Shichiri M., Follansbee M.R., and Sedivy J.M. Effects of c-myc expression on cell cycle progression. Mol Cell Biol 14 (1994) 5748-5755
31. Watson P.H., Pon R.T., and Shiu R.P. Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51 (1991) 3996-4000
32. Dubik D., and Shiu R.P. Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7 (1992) 1587-1594
33. Clark D.E., Poteet-Smith C.E., Smith J.A., and Lannigan D.A. Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. EMBO J 20 (2001) 3484-3494
34. Joel P.B., Traish A.M., and Lannigan D.A. Estradiol-induced phosphorylation of serine 118 in the estrogen receptor is independent of p42/p44 mitogen-activated protein kinase. J Biol Chem 273 (1998) 13317-13323
35. Joel P.B., Smith J., Sturgill T.W., Fisher T.L., Blenis J., and Lannigan D.A. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol 18 (1998) 1978-1984
36. Joel P.B., Traish A.M., and Lannigan D.A. Estradiol and phorbol ester cause phosphorylation of serine 118 in the human estrogen receptor. Mol Endocrinol 9 (1995) 1041-1052
37. Sutherland R.L., and Musgrove E.A. Cyclins and breast cancer. J Mammary Gland Biol Neoplasia 9 (2004) 95-104
38. Eisinger-Mathason T.S., Andrade J., Groehler A.L., Clark D.E., Muratore-Schroeder T.L., Pasic L., et al. Codependent functions of RSK2 and the apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival. Mol Cell 31 (2008) 722-736
39. Wang T.C., Cardiff R.D., Zukerberg L., Lees E., Arnold A., and Schmidt E.V. Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369 (1994) 669-671
40. Kedersha N., Chen S., Gilks N., Li W., Miller I.J., Stahl J., et al. Evidence that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient preinitiation complexes are core constituents of mammalian stress granules. Mol Biol Cell 13 (2002) 195-210
41. Anderson P., and Kedersha N. RNA granules. J Cell Biol 172 (2006) 803-808
42. Arimoto K., Fukuda H., Imajoh-Ohmi S., Saito H., and Takekawa M. Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK pathways. Nat Cell Biol 10 (2008) 1324-1332
43. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
44. Lopez de Silanes I., Galban S., Martindale J.L., Yang X., Mazan-Mamczarz K., Indig F.E., et al. Identification and functional outcome of mRNAs associated with RNA-binding protein TIA-1. Mol Cell Biol 25 (2005) 9520-9531
45. Stratford A.L., Fry C.J., Desilets C., Davies A.H., Cho Y.Y., Li Y., et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res 10 (2008) R99
46. Finkbeiner M.R., Astanehe A., To K., Fotovati A., Davies A.H., Zhao Y., et al. Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells. Oncogene 28 (2009) 1421-1431
47. Stratford A.L., Habibi G., Astanehe A., Jiang H., Hu K., Park E., et al. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 9 (2007) R61
48. Habibi G., Leung S., Law J.H., Gelmon K., Masoudi H., Turbin D., et al. Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res 10 (2008) R86
49. Lee C., Dhillon J., Wang M.Y., Gao Y., Hu K., Park E., et al. Targeting YB-1 in HER-2 overexpressing breast cancer cells induces apoptosis via the mTOR/STAT3 pathway and suppresses tumor growth in mice. Cancer Res 68 (2008) 8661-8666
50. Faury D., Nantel A., Dunn S.E., Guiot M.C., Haque T., Hauser P., et al. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25 (2007) 1196-1208
51. Bergmann S., Royer-Pokora B., Fietze E., Jurchott K., Hildebrandt B., Trost D., et al. YB-1 provokes breast cancer through the induction of chromosomal instability that emerges from mitotic failure and centrosome amplification. Cancer Res 65 (2005) 4078-4087
52. Sutherland B.W., Kucab J., Wu J., Lee C., Cheang M.C., Yorida E., et al. Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene 24 (2005) 4281-4292
53. Fujii T., Kawahara A., Basaki Y., Hattori S., Nakashima K., Nakano K., et al. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers. Cancer Res 68 (2008) 1504-1512
54. Burd C.J., Petre C.E., Morey L.M., Wang Y., Revelo M.P., Haiman C.A., et al. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation. Proc Natl Acad Sci USA 103 (2006) 2190-2195
55. Suzuki H., Ueda T., Ichikawa T., and Ito H. Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer 10 (2003) 209-216
56. Taplin M.E., and Balk S.P. Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91 (2004) 483-490
57. La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev 10 (2001) 125-129
58. Hatch K.D., Beecham J.B., Blessing J.A., and Creasman W.T. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer 68 (1991) 269-271
59. Scambia G., Benedetti-Panici P., Ferrandina G., Distefano M., Salerno G., Romanini M.E., et al. Epidermal growth factor, oestrogen and progesterone receptor expression in primary ovarian cancer: correlation with clinical outcome and response to chemotherapy. Br J Cancer 72 (1995) 361-366
60. Rao B.R., and Slotman B.J. Endocrine factors in common epithelial ovarian cancer. Endocr Rev 12 (1991) 14-26
61. Pohl G., Ho C.L., Kurman R.J., Bristow R., Wang T.L., and Shih Ie M. Inactivation of the mitogen-activated protein kinase pathway as a potential target-based therapy in ovarian serous tumors with KRAS or BRAF mutations. Cancer Res 65 (2005) 1994-2000
62. Nakayama N., Nakayama K., Yeasmin S., Ishibashi M., Katagiri A., Iida K., et al. KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer. Br J Cancer 99 (2008) 2020-2028
63. Albanito L., Madeo A., Lappano R., Vivacqua A., Rago V., Carpino A., et al. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells. Cancer Res 67 (2007) 1859-1866
64. Chen R.H., Juo P.C., Curran T., and Blenis J. Phosphorylation of c-Fos at the C-terminus enhances its transforming activity. Oncogene 12 (1996) 1493-1502
65. Chen R.H., Abate C., and Blenis J. Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci USA 90 (1993) 10952-10956
66. Renoir J.M., Bouclier C., Seguin A., Marsaud V., and Sola B. Antioestrogen-mediated cell cycle arrest and apoptosis induction in breast cancer and multiple myeloma cells. J Mol Endocrinol 40 (2008) 101-112
67. Gauduchon J., Seguin A., Marsaud V., Clay D., Renoir J.M., and Sola B. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases. Int J Cancer 122 (2008) 2130-2141
68. Otsuki T., Yamada O., Kurebayashi J., Moriya T., Sakaguchi H., Kunisue H., et al. Estrogen receptors in human myeloma cells. Cancer Res 60 (2000) 1434-1441
69. Zhan F., Hardin J., Kordsmeier B., Bumm K., Zheng M., Tian E., et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood 99 (2002) 1745-1757
70. Cicatiello L., Addeo R., Sasso A., Altucci L., Petrizzi V.B., Borgo R., et al. Estrogens and progesterone promote persistent CCND1 gene activation during G1 by inducing transcriptional derepression via c-Jun/c-Fos/estrogen receptor (progesterone receptor) complex assembly to a distal regulatory element and recruitment of cyclin D1 to its own gene promoter. Mol Cell Biol 24 (2004) 7260-7274
71. Chesi M., Nardini E., Brents L.A., Schrock E., Ried T., Kuehl W.M., et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet 16 (1997) 260-264
72. Kang S., Dong S., Gu T.L., Guo A., Cohen M.S., Lonial S., et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell 12 (2007) 201-214
73. Roux P.P., Richards S.A., and Blenis J. Phosphorylation of p90 ribosomal S6 kinase (RSK) regulates extracellular signal-regulated kinase docking and RSK activity. Mol Cell Biol 23 (2003) 4796-4804
74. Kang S., Elf S., Dong S., Hitosugi T., Lythgoe K., Guo A., et al. FGFR3 associates with and tyrosine-phosphorylates p90RSK2, leading to RSK2 activation that mediates hematopoietic transformation. Mol Cell Biol (2009)
75. Poteet-Smith C.E., Smith J.A., Lannigan D.A., Freed T.A., and Sturgill T.W. Generation of constitutively active p90 ribosomal S6 kinase in vivo. Implications for the mitogen-activated protein kinase-activated protein kinase family. J Biol Chem 274 (1999) 22135-22138
76. Rickard D.J., Subramaniam M., and Spelsberg T.C. Molecular and cellular mechanisms of estrogen action on the skeleton. J Cell Biochem Suppl 32/33 (1999) 123-132
77. Zallone A. Direct and indirect estrogen actions on osteoblasts and osteoclasts. Ann N Y Acad Sci 1068 (2006) 173-179
78. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H.C., Schinke T., et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry syndrome. Cell 117 (2004) 387-398
79. Kang S., Dong S., Guo A., Ruan H., Lonial S., Khoury H.J., et al. Epidermal growth factor stimulates RSK2 activation through activation of the MEK/ERK pathway and src-dependent tyrosine phosphorylation of RSK2 at Tyr-529. J Biol Chem 283 (2008) 4652-4657
80. Kang S., Dong S., Guo A., Ruan H., Lonial S., Khoury H.J., et al. EGF stimulates RSK2 activation through activation of the MEK/ERK pathway and Src-dependent tyrosine phosphorylation of RSK2 at Y529. J Biol Chem (2007)
81. Summy J.M., and Gallick G.E. Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22 (2003) 337-358
82. Schwartz A.G., Wenzlaff A.S., Prysak G.M., Murphy V., Cote M.L., Brooks S.C., et al. Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women. J Clin Oncol 25 (2007) 5785-5792
83. Kaiser U., Hofmann J., Schilli M., Wegmann B., Klotz U., Wedel S., et al. Steroid-hormone receptors in cell lines and tumor biopsies of human lung cancer. Int J Cancer 67 (1996) 357-364
84. Chaudhuri P.K., Thomas P.A., Walker M.J., Briele H.A., Das Gupta T.K., and Beattie C.W. Steroid receptors in human lung cancer cytosols. Cancer Lett 16 (1982) 327-332
85. Beattie C.W., Hansen N.W., and Thomas P.A. Steroid receptors in human lung cancer. Cancer Res 45 (1985) 4206-4214
86. Hammoud Z., Tan B., Badve S., and Bigsby R.M. Estrogen promotes tumor progression in a genetically defined mouse model of lung adenocarcinoma. Endocr Relat Cancer 15 (2008) 475-483
87. Bertolotto C., Maulon L., Filippa N., Baier G., and Auberger P. Protein kinase C theta and epsilon promote T-cell survival by a rsk-dependent phosphorylation and inactivation of BAD. J Biol Chem 275 (2000) 37246-37250
88. Bonni A., Brunet A., West A.E., Datta S.R., Takasu M.A., and Greenberg M.E. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 286 (1999) 1358-1362
89. Zha J., Harada H., Yang E., Jockel J., and Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not BCL-X(L). Cell 87 (1996) 619-628
90. Fernando R.I., and Wimalasena J. Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. Mol Biol Cell 15 (2004) 3266-3284
91. Boland R., Vasconsuelo A., Milanesi L., Ronda A.C., and de Boland A.R. 17Beta-estradiol signaling in skeletal muscle cells and its relationship to apoptosis. Steroids 73 (2008) 859-863
92. Fernandes A.M., Hamburger A.W., and Gerwin B.I. Production of epidermal growth factor related ligands in tumorigenic and benign human lung epithelial cells. Cancer Lett 142 (1999) 55-63
93. Werner H., and LeRoith D. The role of the insulin-like growth factor system in human cancer. Adv Cancer Res 68 (1996) 183-223
94. Hurbin A., Dubrez L., Coll J.L., and Favrot M.C. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 277 (2002) 49127-49133
95. Leung L.K., Do L., and Wang T.T. Regulation of death promoter Bak expression by cell density and 17 beta-estradiol in MCF-7 cells. Cancer Lett 124 (1998) 47-52
96. Fletcher J.I., and Huang D.C. Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle 7 (2008) 39-44
97. Cohen C., DeRose P.B., Campbell W.G., Schlosnagle D.C., and Sgoutas D. Estrogen receptor status in malignant melanoma. Am J Dermatopathol 12 (1990) 562-564
98. Fisher R.I., Neifeld J.P., and Lippman M.E. Oestrogen receptors in human malignant melanoma. Lancet 2 (1976) 337-339
99. Walker M.J., Beattie C.W., Patel M.K., Ronan S.M., and Das Gupta T.K. Estrogen receptor in malignant melanoma. J Clin Oncol 5 (1987) 1256-1261
100. de Giorgi V., Mavilia C., Massi D., Gozzini A., Aragona P., Tanini A., et al. Estrogen receptor expression in cutaneous melanoma: a real-time reverse transcriptase-polymerase chain reaction and immunohistochemical study. Arch Dermatol 145 (2009) 30-36
101. Gill P.G., De Young N.J., Thompson A., Keightley D.D., and Horsfall D.J. The effect of tamoxifen on the growth of human malignant melanoma in vitro. Eur J Cancer Clin Oncol 20 (1984) 807-815
102. Cocconi G., Bella M., Calabresi F., Tonato M., Canaletti R., Boni C., et al. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 327 (1992) 516-523
103. Cocconi G. High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma. Cancer 70 (1992) 902
104. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., and Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci USA 101 (2004) 13489-13494
105. Ohta Y., and Hartwig J.H. Phosphorylation of actin-binding protein 280 by growth factors is mediated by p90 ribosomal protein S6 kinase. J Biol Chem 271 (1996) 11858-11864
106. Woo M.S., Ohta Y., Rabinovitz I., Stossel T.P., and Blenis J. Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol Cell Biol 24 (2004) 3025-3035
107. Byers H.R., Etoh T., Doherty J.R., Sober A.J., and Mihm Jr. M.C. Cell migration and actin organization in cultured human primary, recurrent cutaneous and metastatic melanoma. Time-lapse and image analysis. Am J Pathol 139 (1991) 423-435
108. Larrea M.D., Hong F., Wander S.A., da Silva T.G., Helfman D., Lannigan D., et al. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci USA 106 (2009) 9268-9273
109. Doehn U., Hauge C., Frank S.R., Jensen C.J., Duda K., Nielsen J.V., et al. RSK is a principal effector of the RAS-ERK pathway for eliciting a coordinate promotile/invasive gene program and phenotype in epithelial cells. Mol Cell 35 (2009) 511-522
110. Dohi O., Hatori M., Suzuki T., Ono K., Hosaka M., Akahira J., et al. Sex steroid receptors expression and hormone-induced cell proliferation in human osteosarcoma. Cancer Sci 99 (2008) 518-523
111. Walker M.J., Chaudhuri P.K., Beattie C.W., and Das Gupta T.K. Steroid receptors in malignant skeletal tumors. Cancer 45 (1980) 3004-3007
112. Duan R., Porter W., and Safe S. Estrogen-induced c-fos protooncogene expression in MCF-7 human breast cancer cells: role of estrogen receptor Sp1 complex formation. Endocrinology 139 (1998) 1981-1990
113. Weisz A., and Rosales R. Identification of an estrogen response element upstream of the human c-fos gene that binds the estrogen receptor and the AP-1 transcription factor. Nucleic Acids Res 18 (1990) 5097-5106
114. Wu J.X., Carpenter P.M., Gresens C., Keh R., Niman H., Morris J.W., et al. The proto-oncogene c-fos is over-expressed in the majority of human osteosarcomas. Oncogene 5 (1990) 989-1000
115. Dony C., and Gruss P. Proto-oncogene c-fos expression in growth regions of fetal bone and mesodermal web tissue. Nature 328 (1987) 711-714
116. Hoyland J., and Sharpe P.T. Upregulation of c-fos protooncogene expression in pagetic osteoclasts. J Bone Miner Res 9 (1994) 1191-1194
117. Candeliere G.A., Glorieux F.H., Prud'homme J., and St-Arnaud R. Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332 (1995) 1546-1551
118. Murphy L.O., Smith S., Chen R.H., Fingar D.C., and Blenis J. Molecular interpretation of ERK signal duration by immediate early gene products. Nat Cell Biol 4 (2002) 556-564
119. Young I.D. The Coffin-Lowry syndrome. J Med Genet 25 (1988) 344-348
120. Hanauer A., and Young I.D. Coffin-Lowry syndrome: clinical and molecular features. J Med Genet 39 (2002) 705-713
121. Yu V.W., Gauthier C., and St-Arnaud R. Inhibition of ATF4 transcriptional activity by FIAT/gamma-taxilin modulates bone mass accrual. Ann N Y Acad Sci 1068 (2006) 131-142
122. Yu V.W., Ambartsoumian G., Verlinden L., Moir J.M., Prud'homme J., Gauthier C., et al. FIAT represses ATF4-mediated transcription to regulate bone mass in transgenic mice. J Cell Biol 169 (2005) 591-601
123. Ameri K., Lewis C.E., Raida M., Sowter H., Hai T., and Harris A.L. Anoxic induction of ATF-4 through HIF-1-independent pathways of protein stabilization in human cancer cells. Blood 103 (2004) 1876-1882
124. Hong S.H., Nah H.Y., Lee J.Y., Gye M.C., Kim C.H., and Kim M.K. Analysis of estrogen-regulated genes in mouse uterus using cDNA microarray and laser capture microdissection. J Endocrinol 181 (2004) 157-167
125. Tonini T., Rossi F., and Claudio P.P. Molecular basis of angiogenesis and cancer. Oncogene 22 (2003) 6549-6556
126. Nakamura J., Savinov A., Lu Q., and Brodie A. Estrogen regulates vascular endothelial growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-induced rat mammary tumors. Endocrinology 137 (1996) 5589-5596
127. Rubanyi G.M., Johns A., and Kauser K. Effect of estrogen on endothelial function and angiogenesis. Vascul Pharmacol 38 (2002) 89-98
128. Johns A., Freay A.D., Fraser W., Korach K.S., and Rubanyi G.M. Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice. Endocrinology 137 (1996) 4511-4513
129. Losordo D.W., and Isner J.M. Estrogen and angiogenesis: a review. Arterioscler Thromb Vasc Biol 21 (2001) 6-12
130. Spyridopoulos I., Sullivan A.B., Kearney M., Isner J.M., and Losordo D.W. Estrogen-receptor-mediated inhibition of human endothelial cell apoptosis. Estradiol as a survival factor. Circulation 95 (1997) 1505-1514
131. Dabrosin C., Palmer K., Muller W.J., and Gauldie J. Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants. Breast Cancer Res Treat 78 (2003) 1-6
132. Hyder S.M., Huang J.C., Nawaz Z., Boettger-Tong H., Makela S., Chiappetta C., et al. Regulation of vascular endothelial growth factor expression by estrogens and progestins. Environ Health Perspect 108 Suppl. 5 (2000) 785-790
133. Esparis-Ogando A., Diaz-Rodriguez E., Montero J.C., Yuste L., Crespo P., and Pandiella A. Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2. Mol Cell Biol 22 (2002) 270-285
134. English J.M., Pearson G., Hockenberry T., Shivakumar L., White M.A., and Cobb M.H. Contribution of the ERK5/MEK5 pathway to Ras/Raf signaling and growth control. J Biol Chem 274 (1999) 31588-31592
135. Hayashi M., Kim S.W., Imanaka-Yoshida K., Yoshida T., Abel E.D., Eliceiri B., et al. Targeted deletion of BMK1/ERK5 in adult mice perturbs vascular integrity and leads to endothelial failure. J Clin Invest 113 (2004) 1138-1148
136. Hayashi M., Fearns C., Eliceiri B., Yang Y., and Lee J.D. Big mitogen-activated protein kinase 1/extracellular signal-regulated kinase 5 signaling pathway is essential for tumor-associated angiogenesis. Cancer Res 65 (2005) 7699-7706
137. Geraghty K.M., Chen S., Harthill J.E., Ibrahim A.F., Toth R., Morrice N.A., et al. Regulation of multisite phosphorylation and 14-3-3 binding of AS160 in response to IGF-1, EGF, PMA and AICAR. Biochem J 407 (2007) 231-241
138. Shimamura A., Ballif B.A., Richards S.A., and Blenis J. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol 10 (2000) 127-135
139. Chaturvedi D., Cohen M.S., Taunton J., and Patel T.B. The PKARI{alpha} subunit of protein kinase A modulates the activation of p90RSK1 and its function. J Biol Chem 684 (2009) 23670-23681
140. Abe Y., Yoon S.O., Kubota K., Mendoza M.C., Gygi S.P., and Blenis J. p90 ribosomal S6 kinase and p70 ribosomal S6 kinase link phosphorylation of the eukaryotic chaperonin containing TCP-1 to growth factor, insulin, and nutrient signaling. J Biol Chem 684 (2009) 14939-14948
141. Lee S.J., and Kim S.G. Role of p90 ribosomal S6-kinase-1 in oltipraz-induced specific phosphorylation of CCAAT/enhancer binding protein-beta for GSTA2 gene transactivation. Mol Pharmacol 69 (2006) 385-396
142. Buck M., and Chojkier M. A ribosomal S-6 kinase-mediated signal to C/EBP-beta is critical for the development of liver fibrosis. PLoS One 6 (2007) e1372
143. Anjum R., Roux P.P., Ballif B.A., Gygi S.P., and Blenis J. The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol 15 (2005) 1762-1767
144. Wang X., Li W., Williams M., Terada N., Alessi D.R., and Proud C.G. Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 60 (2001) 4370-4379
145. Roberts N.A., Haworth R.S., and Avkiran M. Effects of bisindolylmaleimide PKC inhibitors on p90RSK activity in vitro and in adult ventricular myocytes. Br J Pharmacol 145 (2005) 477-489
146. Kroczynska B., Kaur S., Katsoulidis E., Majchrzak-Kita B., Sassano A., Kozma S.C., et al. Interferon-dependent engagement of eukaryotic initiation factor 4B via S6 kinase (S6K)- and ribosomal protein S6K-mediated signals. Mol Cell Biol 69 (2009) 2865-2875
147. Shahbazian D., Roux P.P., Mieulet V., Cohen M.S., Raught B., Taunton J., et al. The mTOR/PI3K and MAPK pathways converge on eIF4B to control its phosphorylation and activity. EMBO J 65 (2006) 2781-2791
148. Joel P.B., Smith J., Sturgill T.W., Fisher T.L., Blenis J., and Lannigan D.A. pp90rsk1 regulates estrogen receptor-mediated transcription through phosphorylation of Ser-167. Mol Cell Biol. 18 (1998) 1978-1984
149. Wu J., and Janknecht R. Regulation of the ETS transcription factor ER81 by the 90-kDa ribosomal S6 kinase 1 and protein kinase A. J Biol Chem 677 (2002) 42669-42679
150. Woo M.S., Ohta Y., Rabinovitz I., Stossel T.P., and Blenis J. Ribosomal S6 kinase (RSK) regulates phosphorylation of filamin A on an important regulatory site. Mol Cell Biol 64 (2004) 3025-3035
151. Ghoda L., Lin X., and Greene W.C. The 90-kDa ribosomal S6 kinase (pp90rsk) phosphorylates the N-terminal regulatory domain of IkappaBalpha and stimulates its degradation in vitro. J Biol Chem 676 (1997) 21281-21288
152. Xu S., Bayat H., Hou X., and Jiang B. Ribosomal S6 kinase-1 modulates interleukin-1beta-induced persistent activation of NF-kappaB through phosphorylation of IkappaBbeta. Am J Physiol Cell Physiol 691 (2006) C1336-C1345
153. Sapkota G.P., Kieloch A., Lizcano J.M., Lain S., Arthur J.S., Williams M.R., et al. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell vrowth. J Biol Chem 676 (2001) 19469-19482
154. Zhu J., Blenis J., and Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc Natl Acad Sci U S A 105 (2008) 6584-6589
155. Palmer A., Gavin A.C., and Nebreda A.R. A link between MAP kinase and p34(cdc2)/cyclin B during oocyte maturation: p90(rsk) phosphorylates and inactivates the p34(cdc2) inhibitory kinase Myt1. EMBO J 17 (1998) 5037-5047
156. Wu M., Hemesath T.J., Takemoto C.M., Horstmann M.A., Wells A.G., Price E.R., et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 14 (2000) 301-312
157. Song T., Sugimoto K., Ihara H., Mizutani A., Hatano N., Kume K., et al. p90 RSK-1 associates with and inhibits neuronal nitric oxide synthase. Biochem J 401 (2007) 391-398
158. Fujita N., Sato S., and Tsuruo T. Phosphorylation of p27Kip1 at threonine 198 by p90 ribosomal protein S6 kinases promotes its binding to 14-3-3 and cytoplasmic localization. J Biol Chem 678 (2003) 49254-49260
159. Larrea M.D., Hong F., Wander S.A., da Silva T.G., Helfman D., Lannigan D., et al. RSK1 drives p27Kip1 phosphorylation at T198 to promote RhoA inhibition and increase cell motility. Proc Natl Acad Sci U S A 106 (2009) 9268-9273
160. Carriere A., Cargnello M., Julien L.A., Gao H., Bonneil E., Thibault P., et al. Oncogenic MAPK signaling stimulates mTORC1 activity by promoting RSK-mediated raptor phosphorylation. Curr Biol 18 (2008) 1269-1277
161. Yoon S.O., Shin S., Liu Y., Ballif B.A., Woo M.S., Gygi S.P., et al. Ran-binding protein 3 phosphorylation links the Ras and PI3-kinase pathways to nucleocytoplasmic transport. Mol Cell 69 (2008) 362-375
162. Roux P.P., Shahbazian D., Vu H., Holz M.K., Cohen M.S., Taunton J., et al. RAS/ERK signaling promotes site-specific ribosomal protein S6 phosphorylation via RSK and stimulates cap-dependent translation. J Biol Chem 686 (2007) 14056-14064
163. Roux P.P., Ballif B.A., Anjum R., Gygi S.P., and Blenis J. Tumor-promoting phorbol esters and activated Ras inactivate the tuberous sclerosis tumor suppressor complex via p90 ribosomal S6 kinase. Proc Natl Acad Sci U S A 101 (2004) 13489-13494
164. Stratford A.L., Fry C.J., Desilets C., Davies A.H., Cho Y.Y., Li Y., et al. Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Res. 10 (2008) R99
165. Astanehe A., Finkbeiner M.R., Hojabrpour P., To K., Fotovati A., Shadeo A., et al. The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1. Oncogene 68 (2009) 2406-2418
166. Yang X., Matsuda K., Bialek P., Jacquot S., Masuoka H.C., Schinke T., et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology: implication for Coffin-Lowry syndrome. Cell 117 (2004) 387-398
167. Tan Y., Demeter M.R., Ruan H., and Comb M.J. BAD Ser-155 phosphorylation regulates BAD/Bcl-XL interaction and cell survival. J Biol Chem 675 (2000) 25865-25869
168. She Q.B., Ma W.Y., Zhong S., and Dong Z. Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. J Biol Chem 677 (2002) 24039-24048
169. Clark C.J., McDade D.M., O'Shaughnessy C.T., and Morris B.J. Contrasting roles of neuronal Msk1 and Rsk2 in Bad phosphorylation and feedback regulation of Erk signalling. J Neurochem 106 (2007) 1024-1034
170. Chen R.H., Abate C., and Blenis J. Phosphorylation of the c-Fos transrepression domain by mitogen-activated protein kinase and 90-kDa ribosomal S6 kinase. Proc Natl Acad Sci U S A 90 (1993) 10952-10956
171. David J.P., Mehic D., Bakiri L., Schilling A.F., Mandic V., Priemel M., et al. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest 115 (2005) 664-672
172. Nishiyama T., Ohsumi K., and Kishimoto T. Phosphorylation of Erp1 by p90rsk is required for cytostatic factor arrest in Xenopus laevis eggs. Nature 446 (2007) 1096-1099
173. Clark D.E., Poteet-Smith C.E., Smith J.A., and Lannigan D.A. Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. EMBO J 60 (2001) 3484-3494
174. Wang Y., Liu L., and Xia Z. Brain-derived neurotrophic factor stimulates the transcriptional and neuroprotective activity of myocyte-enhancer factor 2C through an ERK1/2-RSK2 signaling cascade. J Neurochem 106 (2007) 957-966
175. Cho Y.Y., Yao K., Bode A.M., Bergen III H.R., Madden B.J., Oh S.M., et al. RSK2 mediates muscle cell differentiation through regulation of NFAT3. J Biol Chem 686 (2007) 8380-8392
176. Cuello F., Snabaitis A.K., Cohen M.S., Taunton J., and Avkiran M. Evidence for direct regulation of myocardial Na+/H+ exchanger isoform 1 phosphorylation and activity by 90-kDa ribosomal S6 kinase (RSK): effects of the novel and specific RSK inhibitor fmk on responses to alpha1-adrenergic stimulation. Mol Pharmacol 71 (2007) 799-806
177. Wang A., Rud J., Olson Jr. C.M., Anguita J., and Osborne B.A. Phosphorylation of Nur77 by the MEK-ERK-RSK cascade induces mitochondrial translocation and apoptosis in T cells. J Immunol 183 (2009) 3268-3277
178. Wingate A.D., Campbell D.G., Peggie M., and Arthur J.S. Nur77 is phosphorylated in cells by RSK in response to mitogenic stimulation. Biochem J 393 (2006) 715-724
179. Zhang Y., Cho Y.Y., Petersen B.L., Bode A.M., Zhu F., and Dong Z. Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3. J Biol Chem 678 (2003) 12650-12659
180. Zhao J., Yuan X., Frodin M., and Grummt I. ERK-dependent phosphorylation of the transcription initiation factor TIF-IA is required for RNA polymerase I transcription and cell growth. Mol Cell 11 (2003) 405-413
181. Zhao Y., Bjorbaek C., Weremowicz S., Morton C.C., and Moller D.E. RSK3 encodes a novel pp90rsk isoform with a unique N-terminal sequence: growth factor-stimulated kinase function and nuclear translocation. Mol Cell Biol 15 (1995) 4353-4363